New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

CNS Drugs

Volumn 30, Issue 10, 2016, Pages 951-983

  Beard, Emma ^a   Shahab, Lion ^a   Cummings, Damian M ^a   Michie, Susan ^a   West, Robert ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CANNABINOID 1 RECEPTOR ANTAGONIST; CLONIDINE; CYTISINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUGS USED IN THE TREATMENT OF ADDICTION; GLUCOSE; HYPERICUM PERFORATUM EXTRACT; LORCASERIN; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOBREVIN; NICOTINE VACCINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OPIATE ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SEROTONIN UPTAKE INHIBITOR; SILVER ACETATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VARENICLINE; VENLAFAXINE;

ADDICTION; ALLERGIC REACTION; AMBLYOPIA; ANXIETY; ARGYRIA; BLOATING; BODY WEIGHT MANAGEMENT; BREAST TUMOR; COGNITIVE DEFECT; CONSTIPATION; CONVULSION; DEPRESSION; DIZZINESS; DRUG COST; DRUG DELIVERY DEVICE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG USE; ELECTRONIC CIGARETTE; FATIGUE; GABAERGIC TRANSMISSION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HARM REDUCTION; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERHIDROSIS; IRRITABILITY; MENTAL DISEASE; MUSCLE SPASM; MUSCLE TWITCH; MYOCLONUS; NAUSEA; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERCEPTION DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN IRRITATION; SLEEP DISORDER; SMOKING CESSATION; SWEAT GLAND DISEASE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREMOR; URINE RETENTION; VISUAL DISORDER; VOMITING; WATER RETENTION; WEAKNESS; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA; DRUG EFFECTS; DRUG THERAPY; PROCEDURES; SMOKING;

HARM REDUCTION; HUMANS; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION;

EID: 84978897988     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0362-3     Document Type: Review

References (409)

1. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA. 2014;311(2):183–92.
2. World Health Organization. WHO report on the global tobacco epidemic, 2011. 2011. cited; Available from: http://www.who.int/tobacco/global_report/2011/en/.
3. U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the Surgeon General. 2014. cited; Available from: http://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm.
4. Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals—A guide to effective smoking cessation interventions for the health care system. Thorax. 1998;53(suppl 5):S1–18.
5. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Libr. 2013;5(CD009329).
6. Kotz D, Brown J, West R. Prospective cohort study of the effectiveness of smoking cessation treatments used in the “real world”. Mayo Clinic Proceedings: Elsevier; 2014. p. 1360–7.
7. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024.
8. Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R. Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers. Addiction. 2011;106:197–204.
9. Beard E, Michie S, Fidler J, West R. Use of nicotine replacement therapy in situations involving temporary abstinence from smoking: a national survey of English smokers. Addict Behav. 2013;38(3):1876–9.
10. West R, May S, West M, Croghan E, McEwen A. Performance of English stop smoking services in first 10 years: analysis of service monitoring data. BMJ. 2013;347:f4921.
11. Beard E, Vangeli E, Michie S, West R. The use of nicotine replacement therapy for smoking reduction and temporary abstinence: an interview study. Nicotine Tob Res. 2012;14(7):849–56.
12. West R, Raw M, McNeill A, Stead L, Aveyard P, Bitton J, et al. Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addiction. 2015;110:1388–403.
13. Ebell MH, Barry HC, Slawson DC, Shaughnessy AF. Finding POEMs in the medical literature. J Fam Pract. 1999;48(5):350–5.
14. Singal AG, Higgins PDR, Waljee AK. A primer on effectiveness and efficacy trials. Clin Trans Gastroenterol. 2014;5:e45.
15. Kozlowski L, Strasser A, Giovino G, Erickson P, Terza J. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control. 2001;10(3):201.
16. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, et al. The research on adverse drug events and reports (RADAR) project. JAMA. 2005;293(17):2131–40.
17. Taylor R, Drummond M, Salkeld G, Sullivan S. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ Br Med J. 2004;329(7472):972.
18. Wang F, Zhang H, Zang H, Ouyang M. Purchasing pirated software: an initial examination of Chinese consumers. J Consumer Mark. 2005;22(6):340–51.
19. Fiore MC, Jaen CR, Baker T, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, Froelicher ES, Goldstein MG, Healton CG, Henderson PN. Treating tobacco use and dependence: 2008 update. Rockville, MD: US Department of Health and Human Services; 2008.
20. Denford S, Frost J, Dieppe P, Cooper C, Britten N. Individualisation of drug treatments for patients with long-term conditions: a review of concepts. BMJ Open. 2014;4(3):e004172.
21. Gligorijevic V, Malod-Dognin N, Przulj N. Patient-specific data fusion for cancer stratification and personalised treatment. Pac Symp Biocomput. 2016;21:321–32.
22. UK Trade and Investment. Unlock your global business potential: UK stratified medicine. 2013. cited; Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/301775/UK_Stratified_Medicine.pdf.
23. MRC. Stratified medicine. 2016 [cited; Available from: http://www.mrc.ac.uk/research/initiatives/stratified-medicine/.
24. National Collaborating Centre for Primary Care. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. London, England; 2009.
25. Hu T-W, Sung H-Y, Keeler TE, Marciniak M. Cigarette consumption and sales of nicotine replacement products. Tob Control. 2000;9(Suppl 2):ii60–3.
26. Russell MA. Low-tar medium-nicotine cigarettes: a new approach to safer smoking. Br Med J. 1976;1(6023):1430–3.
27. Russell MA, Sutton SR, Feyerabend C, Cole PV, Saloojee Y. Nicotine chewing gum as a substitute for smoking. Br Med J. 1977;1(6068):1060–3.
28. Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991;86(5):571–5.
29. A report of the Surgeon General. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. 2010. cited; Available from: http://www.surgeongeneral.gov/library/reports/.
30. DiFranza JR. Hooked from the first cigarette. Sci Am. 2008;298(5):82–7.
31. Bolliger CT, van Biljon X, Axelsson A. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration. 2007;74(2):196–201.
32. Shahab L, Brose LS, West R. Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems. CNS Drugs. 2013;27(12):1007–19.
33. Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology. 2006;184(3–4):637–44.
34. Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, et al. Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav. 2009;91(3):380–4.
35. Chen LL, Inventor. United States patent application publication (US 20011/0110880 A1): Nicotine Lozenege Composition 2011.
36. NICE. Smoking: harm reduction NICE guidelines [PH45]. 2013. cited; Available from: https://www.nice.org.uk/guidance/ph45.
37. Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Prim Care. 1999;26(3):653–69.
38. Richmond R, Zwar N. Review of bupropion for smoking cessation. Drug Alcohol Rev. 2003;22(2):203–20.
39. Niaura R, Jones C, Kirkpatrick P. Varenicline. Nat Rev Drug Discov. 2006;5(7):537–8.
40. Kasza KA, Cummings KM, Carpenter MJ, Cornelius ME, Hyland AJ, Fong GT. Use of stop-smoking medications in the United States before and after the introduction of varenicline. Addiction. 2015;110(2):346–55.
41. Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;18(4);CD006103.
42. Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992;340(8815):324–9.
43. Shiffman S, Ferguson SG, Rohay J, Gitchell JG. Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction. 2008;103(8):1371–8.
44. Kay J, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with the straw, a novel nicotine replacement product. Nicotine Tob Res. 2004;6(1):63–70.
45. Thornley S, McRobbie H, Lin RB, Bullen C, Hajek P, Laugesen M, et al. A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction. Nicotine Tob Research. 2009;11(6):715–21.
46. Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M. Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol. 2010;18(5):385.
47. Paudel KS, Wu J, Hinds BJ, Stinchcomb AL. Programmable transdermal delivery of nicotine in hairless guinea pigs using carbon nanotube membrane pumps. J Pharm Sci. 2012;101(10):3823–32.
48. Shahab L, McEwen A, West R. Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial. Psychopharmacology. 2011;216(2):187–96.
49. Pichayakorn W, Suksaeree J, Boonme P, Amnuaikit T, Taweepreda W, Ritthidej GC. Deproteinized natural rubber film forming polymeric solutions for nicotine transdermal delivery. Pharm Dev Technol. 2013;18(5):1111–21.
50. Lux J, Frecker R. Subjective responses to inhaled and intravenous injected nicotine. Clinical Pharmacology & Therapeutics; 1988: St Louis: Mosby-Year Book Inc; 1988. p. 186.
51. Strasinger CL, Scheff NN, Wu J, Hinds BJ, Stinchcomb AL. Carbon nanotube membranes for use in the transdermal treatment of nicotine addiction and opioid withdrawal symptoms. Subst Abuse: Res Treat. 2009;3:31.
52. Westman EC, Tomlin KF, Perkins CE, Rose JE. Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob Res. 2001;3(4):391–6.
53. Caldwell B, Sumner W, Crane J. A systematic review of nicotine by inhalation: is there a role for the inhaled route? Nicotine Tob Res. 2012;14(1):1127–39.
54. West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control. 2005;14(3):166–71.
55. Beard E, Brown J, McNeill A, Michie S, West R. Has growth in electronic cigarette use by smokers been responsible for the decline in use of licensed nicotine products? Findings from the Smoking Toolkit Study: a longitudinal cross-sectional survey. Thorax. 2016. doi:10.1136/thoraxjnl-2015-206801.
56. Kotz D, Fidler JA, West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res. 2011;13(9):793–9.
57. Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug LJ. 1998;53:75.
58. Am Ende M, Roy MC, Smith SW, Waterman KC, Moses SK, Quan ES. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene. 2003; PCT Int Appl WO2003045437
59. Waterman KC, Arikpo WB, Fergione MB, Graul TW, Johnson BA, MacDonald BC, et al. N-Methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet. J Pharm Sci. 2008;97(4):1499–507.
60. Johnson BA, Ziegler CB. Transdermal system for varenicline. Google Patents; 2011.
61. Mansour HM, Sohn M, Al-Ghananeem A, Deluca PP. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci. 2010;11(9):3298–322.
62. Kumar VS, Niranjan SK, Irchhaiya R, Neeraj K, Ali A. A noevel transdermal drug delivery system. Int Res J Pharm. 2012;3(8):39–44.
63. George O, Lloyd A, Carroll FI, Damaj MI, Koob GF. Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psychopharmacology. 2011;213(4):715–22.
64. DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry. 2003;64(Suppl 18):14–9.
65. Sedlacek H-H, Sapienza AM, Eid V. Ways to successful strategies in drug research and development. Wiley; 2008.
66. Stapleton J. Is varenicline cost-effective enough to be funded by the NHS now? 2006. cited; Available from: http://www.ash.org.uk/files/documents/ASH_446.pdf.
67. Langley TE, Huang Y, McNeill A, Coleman T, Szatkowski L, Lewis S. Prescribing of smoking cessation medication in England since the introduction of varenicline. Addiction. 2011;106(7):1319–24.
68. Meyer TE, Taylor LG, Xie S, Graham DJ, Mosholder AD, Williams JR, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction. 2013;108(1):203–10.
69. Pasternak B, Svanström H, Hviid A. Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction. 2013;108(7):1336–43.
70. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012;344:e2856.
71. Jeong SH, Newcombe D, Sheridan J, Tingle M. Pharmacokinetics of cytisine, an a4b2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal. 2014;7(6):475–82.
72. Barlow RB, McLeod LJ. Some studies on cytisine and its methylated derivatives. Br J Pharmacol. 1969;35(1):161–74.
73. Reavill C, Walther B, Stolerman IP, Testa B. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology. 1990;29(7):619–24.
74. Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med. 2006;166(15):1553–9.
75. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax. 2013;68(11):1037–42.
76. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:Cd006103.
77. Walker N, Howe C, Glover M, McRobbie H, Barnes J, Nosa V, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med. 2014;371(25):2353–62.
78. Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Health Technol Assess. 2014;18(33):1–120.
79. Samet JM. Cytisine is effective for smoking cessation: should clinicians use it? Evid Based Med. 2014;18:2014.
80. Filippidis FT, Gerovasili V, Vardavas CI, Agaku IT, Tountas Y. Determinants of use of smoking cessation aids in 27 European countries. Prev Med. 2014;65:99–102.
81. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O’Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014;312(2):155–61.
82. Jiloha RC. Pharmacotherapy of smoking cessation. Indian Journal of Psychiatry. 2014;56(1):87–95.
83. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;1:CD000031.
84. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res. 2005;7(4):491–9.
85. Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ. 2008;336(7655):1223–7.
86. Wagena EJ, Knipschild P, Zeegers MP. Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction. 2005;100(3):317–26.
87. Hall SM, Lightwood JM, Humfleet GL, Bostrom A, Reus VI, Munoz R. Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. J Behav Health Serv Res. 2005;32(4):381–92.
88. McRobbie H, Bullen C, Glover M, Whittaker R, Wallace-Bell M, Fraser T. New Zealand smoking cessation guidelines. N Z Med J. 2008;121(1276):57–70.
89. Dawkins L. Electronic cigarettes: what are they and are they effective? E-Cigarette Summit, London, UK: (oral presentation). 2013. cited; Available from: http://e-cigarette-summit.com/wp-content/uploads/2013/12/Summit-Presentations.pdf.
90. Torjesen I. E-cigarettes are to be regulated as medicines from 2016. BMJ. 2013;346:f3859.
91. MHRA. Nicotine containing products. 2013. cited; Available from: www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice–M–T/Nicotinecontainingproducts/index.htm.
92. MHRA. UKPAR e-Voke 10 & 15 mg electronic inhaler. 2015. cited; Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con616843.pdf.
93. McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Libr. 2014;12:CD010216.
94. Brown J, Beard E, Kotz D, Michie S, West R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction. 2014;109(9):1531–40.
95. Adkison SE, O’Connor RJ, Bansal-Travers M, Hyland A, Borland R, Yong H-H, et al. Electronic nicotine delivery systems: international tobacco control four-country survey. Am J Prev Med. 2013;44(3):207–15.
96. Etter J-F, Bullen C. A longitudinal study of electronic cigarette users. Addict Behav. 2014;39(2):491–4.
97. Brose LS, Hitchman SC, Brown J, West R, McNeill A. Is use of electronic cigarettes while smoking associated with smoking cessation attempts, cessation and reduced cigarette consumption? A survey with a 1-year follow-up. Addiction. 2015; 110(7):1160–8.
98. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol. 2002;3(8):461–9.
99. Westenberger B. Evaluation of e-cigarettes. St Louis: Food and Drug Administration; 2009. p. 1–8.
100. Hadwiger ME, Trehy ML, Ye W, Moore T, Allgire J, Westenberger B. Identification of amino-tadalafil and rimonabant in electronic cigarette products using high pressure liquid chromatography with diode array and tandem mass spectrometric detection. J Chromatogr A. 2010;1217(48):7547–55.
101. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob control. 2014;23(2):133–9.
102. Williams M, Villarreal A, Bozhilov K, Lin S, Talbot P. Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol. PLoS One. 2013;8(3):e57987.
103. Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014;5(2):67–86.
104. Hajek P, Etter J-F, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014;109(11):1801–10.
105. McNeill A, Brose L, Calder R, Hitchman S, Hajek P, McRobbie H. E-cigarettes: an evidence update. A report commissioned by Public Health England. Public Health England. 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/457102/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf. Accessed 22 Aug 2015.
106. NHS Choices. News analysis: E-cigarettes to be regulated as medicines. 2013. http://www.nhs.uk/news/2013/06June/Pages/e-cigarettes-and-vaping.aspx.
107. NCSCT. Electronic cigarettes: A briefing for stop smoking services. 2016. cited; Available from: http://www.ncsct.co.uk/usr/pub/Electronic%20cigarettes.%20A%20briefing%20for%20stop%20smoking%20services.pdf.
108. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382(9905):1629–37.
109. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Libr. 2000;2:CD000031.
110. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, et al. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA. 1988;259(19):2863–6.
111. Prochazka AV, Petty TL, Nett L, et al. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med. 1992;152(10):2065–9.
112. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Treating tobacco use and dependence: a clinical practice guideline. Publications Clearinghouse; 2000.
113. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004(3):Cd000058.
114. Ornish SA, Zisook S, McAdams L. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation: a randomized, controlled trial. Arch Intern Med. 1988;148(9):2027–31.
115. Franks P, Harp J, Bell B. Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. JAMA. 1989;262(21):3011–3.
116. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW. Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry. 1991;48(1):52–9.
117. Charles J Bentz. Review: clonidine is more effective than placebo for long term smoking cessation, but has side effects. Evid Based Med. 2005;10(1):19.
118. American Cancer Society. Prescription drugs to help you quit smoking. 2014. http://www.cancer.org/healthy/stayawayfromtobacco/guidetoquittingsmoking/prescription-drugs-to-help-you-quit-smoking
119. Luger TM, Suls J, Vander Weg MW. How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models. Addict Behav. 2014;39(10):1418–29.
120. Nowakowska E, Kus K, Florek E, Czubak A, Jodynis-Liebert J. The influence of tobacco smoke and nicotine on antidepressant and memory-improving effects of venlafaxine. Hum Exp Toxicol. 2006;25(4):199–209.
121. Cinciripini PM, Tsoh JY, Wetter DW, Lam C, de Moor C, Cinciripini L, et al. Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp Clin Psychopharmacol. 2005;13(4):282.
122. Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–51.
123. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006;26(5):482–8.
124. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14(3):175–82.
125. Khalifa M, Daleau P, Turseon DB. Block of sodium channels underlies unheraldded cardiac toxicity observed with the antidepressant agent venlafaxine. J Mol Cell Cardiol. 1998;30:A136.
126. Lenox-Smith A, Greenstreet L, Burslem K, Knight C. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clin Drug Investig. 2009;29(3):173–84.
127. Holliday SM, Benfield P. Venlafaxine. Drugs. 1995;49(2):280–94.
128. Schuller HM, Jull BA, Sheppard BJ, Plummer HK. Interaction of tobacco-specific toxicants with the neuronal α7 nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders. Eur J Pharmacol. 2000;393(1):265–77.
129. Stead L, Hughes J. Can lobeline help people to quit smoking. Health. 2012;2:CD000124.
130. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology. 2003;28(3):542–51.
131. Johnstone TB, Hogenkamp DJ, Coyne L, Su J, Halliwell RF, Tran MB, et al. Modifying quinolone antibiotics yields new anxiolytics. Nat Med. 2004;10(1):31–2.
132. Crooks PA, Bardo MT, Dwoskin LP. Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol (San Diego, Calif). 2014;69:513–51.
133. ®): an old antihypertensive with new research directions. J Hum Hypertens. 2002;16(7):453–7.
134. Rose J, Behm F, Westman E. Brand-switching and gender effects in mecamylamine/nicotine smoking cessation treatment. Nicotine Tob Res. 1999;1:286–7.
135. Leonard S, Adams CE. Smoking cessation and schizophrenia. Am J Psychiatry. 2006;163(11):1877.
136. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(8):1040–7.
137. Tuan EW, Horti AG, Olson TT, Gao Y, Stockmeier CA, Al-Muhtasib N, et al. AT-1001 is a partial agonist with high affinity and selectivity at human and rat alpha3beta4 nicotinic cholinergic receptors. Mol Pharmacol. 2015;88(4):640–9.
138. Yoshimura RF, Hogenkamp DJ, Li WY, Tran MB, Belluzzi JD, Whittemore ER, et al. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. J Pharmacol Exp Ther. 2007;323(3):907–15.
139. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther. 1994;56(1):86–99.
140. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. The Cochrane Library. 1998.
141. Cucchiaro G, Xiao Y, Gonzalez-Sulser A, Kellar KJ. Analgesic effects of sazetidine-A, a new nicotinic cholinergic drug. Anesthesiology. 2008;109(3):512–9.
142. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002;27(3):479–97.
143. West R. Glucose for smoking cessation. CNS drugs. 2001;15(4):261–5.
144. West R, May S, McEwen A, McRobbie H, Hajek P, Vangeli E. A randomised trial of glucose tablets to aid smoking cessation. Psychopharmacology. 2010;207(4):631–5.
145. McRobbie H, Hajek P. Effect of glucose on tobacco withdrawal symptoms in recent quitters using bupropion or nicotine replacement. Hum Psychopharmacol. 2004;19(1):57–61.
146. Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol. 1993;61(5):743–50.
147. Pentel PR, LeSage MG. New directions in nicotine vaccine design and use. Adv Pharmacol (San Diego, Calif). 2014;69:553–80.
148. Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, Murtaugh MP, et al. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol. 2012;83(4):543–50.
149. de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine. 2013;31(52):6185–93.
150. LeSage MG, Shelley D, Pravetoni M, Pentel PR. Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist. Pharmacol Biochem Behav. 2012;102(1):157–62.
151. Selecta Biosciences. Recent news. Selecta Biosciences initiates phase 1 clinical study of SEL-068, a first-in-class synthetic nicotine vaccine for smoking cessation and relapse prevention. 2011. cited; Available from: http://www.selectabio.com/news/recent-news/Selecta-Biosciences-Initiates-Phase-1-Clinical-Study-of-SEL-068.cfm.
152. Brimijoin S, Shen X, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines. 2013;12(3):323–32.
153. Cerny EH, Levy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, et al. Preclinical development of a vaccine ‘against smoking’. Onkologie. 2002;25(5):406–11.
154. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol. 2005;35(7):2031–40.
155. Pravetoni M, Keyler DE, Raleigh MD, Harris AC, Lesage MG, Mattson CK, et al. Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem Pharmacol. 2011;81(9):1164–70.
156. Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol. 2003;3(7):957–70.
157. LeSage MG, Keyler DE, Hieda Y, Collins G, Burroughs D, Le C, et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology. 2006;184(3–4):409–16.
158. Lindblom N, de Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration. 2002;69(3):254–60.
159. Fahim RE, Kessler PD, Kalnik MW. Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines. 2013;12(3):333–42.
160. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89(3):392–9.
161. Tonstad S, Heggen E, Giljam H, Lagerback PA, Tonnesen P, Wikingsson LD, et al. Niccine(R), a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res. 2013;15(9):1492–501.
162. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008;3(6):e2547.
163. Lockner JW, Lively JM, Collins KC, Vendruscolo JC, Azar MR, Janda KD. A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity. J Med Chem. 2015;58(2):1005–11.
164. Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, van Schayck OC. Efficacy of the nicotine vaccine 3′-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction. 2014;109(8):1252–9.
165. Pittet L, Altreuter D, Ilyinskii P, Fraser C, Gao Y, Baldwin S, et al. Development and preclinical evaluation of SEL-068, a novel targeted synthetic vaccine particle (tSVP™) for smoking cessation and relapse prevention that generates high titers of antibodies against nicotine. J Immunol. 2012;188(Meeting Abstracts 1):75.11.
166. Desai RI, Bergman J. Effects of the nanoparticle-based vaccine, SEL-068, on nicotine discrimination in squirrel monkeys. Neuropsychopharmacology. 2015;40(9):2207–16
167. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, Vos A, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78(5):456–67.
168. Gartner CE, Barendregt JJ, Wallace A, Hall WD. Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents? Addiction. 2012;107(4):801–9.
169. Shen X, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther. 2012;91(1):60–70.
170. Raupach T, Hoogsteder PH, Onno van Schayck CP. Nicotine vaccines to assist with smoking cessation: current status of research. Drugs. 2012;72(4):e1–16.
171. Hammond D, Reid JL, Driezen P, Cummings KM, Borland R, Fong GT, et al. Smokers’ use of nicotine replacement therapy for reasons other than stopping smoking: findings from the ITC Four Country Survey. Addiction. 2008;103(10):1696–703.
172. Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs. 2008;68(8):1067–88.
173. Jackson A, Nesic J, Groombridge C, Clowry O, Rusted J, Duka T. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology. 2009;34(2):257–65.
174. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett. 1997;231(3):123–6.
175. Shinn AK, Greenfield SF. Topiramate in the treatment of substance related disorders: a critical review of the literature. J Clin Psychiatry. 2010;71(5):634.
176. Simeone TA, Wilcox KS, White HS. Subunit selectivity of topiramate modulation of heteromeric GABAA receptors. Neuropharmacology. 2006;50(7):845–57.
177. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039–48.
178. Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC psychiatry. 2011;11(1):41.
179. Dunn KE, Marcus TF, Kim C, Schroeder JR, Vandrey R, Umbricht A. Zonisamide reduces withdrawal symptoms but does not enhance varenicline-induced smoking cessation. Nicotine Tob Res. 2015;17:2015.
180. Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013;36(3):237–51.
181. Parker DAS, Ong J, Marino V, Kerr DIB. Gabapentin activates presynaptic GABA B heteroreceptors in rat cortical slices. Eur J Pharmacol. 2004;495(2–3):137–43.
182. Sofuoglu M, Mouratidis M, Yoo S, Culligan K, Kosten T. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology. 2005;181(3):504–10.
183. Eckstein-Ludwig U, Fei J, Schwarz W. Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br J Pharmacol. 1999;128(1):92–102.
184. Romberger DJ, Grant K. Alcohol consumption and smoking status: the role of smoking cessation. Biomed Pharmacother. 2004;58(2):77–83.
185. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and relatedconditions. Arch Gen Psychiatry. 2004;61(11):1107–15.
186. Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend. 2009;105(1):33–41.
187. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165(14):1600–5.
188. Anthenelli RM, Blom TJ, McElroy SL, Keck PE. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction. 2008;103(4):687–94.
189. Holes-Lewis KA, Malcolm R, O’Neil PM. Pharmacotherapy of obesity: clinical treatments and considerations. Am J Med Sci. 2013;345(4):284–8.
190. Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, et al. Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res. 2014;16(3):288–96.
191. Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II—preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24(1):67–71.
192. Franklin TR, Harper D, Kampman K, Kildea-McCrea S, Jens W, Lynch KG, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend. 2009;103(1):30–6.
193. Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA. A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology. 2015;232(1):233–43.
194. Myrick H, Malcolm R, Henderson S, McCormick K. Gabapentin for misuse of homemade nicotine nasal spray. Am J Psychiatry. 2001;158(3):498.
195. White WD, Crockford D, el-Guebaly N, Patten S. A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res. 2005;7(5):809–13.
196. Sood A, Ebbert JO, Schroeder DR, Croghan IT, Sood R, Vander Weg MW, et al. Gabapentin for smoking cessation: a preliminary investigation of efficacy. Nicotine Tob Research. 2007;9(2):291–8.
197. Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, et al. Gabapentin for smoking cessation. Nicotine Tob Res. 2010;12(3):300–4.
198. Licata SC, Rowlett JK. Abuse and dependence liability of benzodiazepine-type drugs: GABA A receptor modulation and beyond. Pharmacol Biochem Behav. 2008;90(1):74–89.
199. Khazaal Y, Cornuz J, Bilancioni R, Zullino DF. Topiramate for smoking cessation. Psychiatry Clin Neurosci. 2006;60(3):384–8.
200. Verrotti A, Loiacono G, Di Sabatino F, Zaccara G. The adverse event profile of zonisamide: a meta-analysis. Acta Neurol Scand. 2013;128(5):297–304.
201. Mula M. Topiramate and cognitive impairment: evidence and clinical implications. Ther Adv Drug Saf. 2012;3(6):279–89.
202. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA. 2008;299(10):1121–2.
203. NHS Cumbria Medicines Management Team. Pregablin or gabapentin for neuropathic pain? 2012. cited; Available from: http://www.cumbria.nhs.uk/ProfessionalZone/MedicinesManagement/Guidelines/Pregablin-for-neuropathic-pain.pdf.
204. Brown JS, Papadopoulos G, Neumann PJ, Price M, Friedman M, Menzin J. Cost-effectiveness of migraine prevention: the case of topiramate in the UK. Cephalalgia. 2006;26(12):1473–82.
205. Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, et al. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol. 2011;31(5):597–602.
206. Hara K, Sata T. Inhibitory effect of gabapentin on N-methyl-d-aspartate receptors expressed in Xenopus oocytes. Acta Anaesthesiol Scand. 2007;51(1):122–8.
207. Kim Y-S, Chang H-K, Lee J-W, Sung Y-H, Kim S-E, Shin M-S, et al. Protective effect of gabapentin on N-methyl-d-aspartate-induced excitotoxicity in rat hippocampal CA1 neurons. J Pharmacol Sci. 2009;109(1):144–7.
208. Yeh C-Y, Chung S-C, Tseng F-L, Tsai Y-C, Liu Y-C. Biphasic effects of chronic intrathecal gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats. Acta Anaesthesiol Taiwan. 2011;49(4):144–8.
209. Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van Den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res. 2011;17:211–6.
210. Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci. 2002;22(20):9134–41.
211. Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25(27):6389–93.
212. Varga V, Jenei Z, Janaky R, Saransaari P, Oja SS. Glutathione is an endogenous ligand of rat brain N-methyl-d-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. Neurochem Res. 1997;22(9):1165–71.
213. Ogita K, Kitago T, Nakamuta H, Fukuda Y, Koida M, Ogawa Y, et al. Glutathione-induced inhibition of Na+-independent and -dependent bindings of L-[3H]glutamate in rat brain. Life Sci. 1986;39(25):2411–8.
214. Gere-Pászti E, Jakus J. The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography. Biomed Chromatogr. 2009;23(6):658–64.
215. Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn’t do. Curr Opin Pharmacol. 2007;7(1):69–76.
216. Popik P, Wrobel M, Rygula R, Bisaga A, Bespalov A. Effects of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforcers in mice. Behav Pharmacol. 2003;14(3):237–44.
217. Thuerauf N, Lunkenheimer J, Lunkenheimer B, Sperling W, Bleich S, Schlabeck M, et al. Memantine fails to facilitate partial cigarette deprivation in smokers—no role of memantine in the treatment of nicotine dependency? Journal of neural transmission (Vienna, Austria: 1996). 2007;114(3):351–7.
218. Kavirajan H. Memantine: a comprehensive review of safety and efficacy. 2009;8(1):89–109.
219. McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS drugs. 2014;28(2):95–106.
220. Kavirajan H. Memantine: a comprehensive review of safety and efficacy. 2009.
221. National Institute for Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. NICE Technology Appraisal Guidance. 2011;217.
222. Bisaga A, Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-d-aspartate (NMDA) antagonists. Drug Alcohol Depend. 2000;59(1):1–15.
223. Dani JA. Roles of dopamine signaling in nicotine addiction. Mol Psychiatry. 2003;8(3):255–6.
224. Hurt RD, Ahlskog JE, Croghan GA, Offord KP, Wolter TD, Croghan IT, et al. Carbidopa/levodopa for smoking cessation: a pilot study with negative results. Nicotine Tob Res. 2000;2(1):71–8.
225. Reinholz J, Skopp O, Breitenstein C, Bohr I, Winterhoff H, Knecht S. Compensatory weight gain due to dopaminergic hypofunction: new evidence and own incidental observations. Nutr Metab. 2008;5:35.
226. Jarvik ME, Caskey NH, Wirshing WC, Madsen DC, Iwamoto-Schaap PN, Elins JL. Bromocriptine reduces cigarette smoking. Addiction. 2000;95(8):1173–83.
227. Murphy MFG, Hey K, Johnstone E, Munafo M, Walton R, Willis B, et al. Bromocriptine use is associated with decreased smoking rates. Addict Biol. 2002;7(3):325–8.
228. Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B, Savoia C, et al. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology. 2013;38(2):302–12.
229. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs. 2004;9(1):39–53.
230. The National Collaborating Centre for Chronic Conditions. Parkinson’s Disease: Economic modelling—dopamine agonists. 2006. https://www.nice.org.uk/guidance/cg35/evidence/full-guideline-194930029.
231. Vengeliene V, Leonardi-Essmann F, Perreau-Lenz S, Gebicke-Haerter P, Drescher K, Gross G, et al. The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J. 2006;20(13):2223–33.
232. Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med. 2008;121(4 Suppl 1):S3–10.
233. Ray R, Rukstalis M, Jepson C, Strasser A, Patterson F, Lynch K, et al. Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence. J Psychopharmacol. 2009;23(2):168–76.
234. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203–26.
235. McCarty M, O’Keefe J, DiNicolantonio J. Carvedilol and spirulina may provide important health protection to smokers and other nicotine addicts: a call for pertinent research. Mo Med. 2014;112(1):72–5.
236. Klimek V, Zhu M-Y, Dilley G, Konick L, Overholser JC, Meltzer HY, et al. Effects of long-term cigarette smoking on the human locus coeruleus. Arch Gen Psychiatry. 2001;58(9):821–7.
237. Page ME. The promises and pitfalls of reboxetine. CNS Drug Rev. 2003;9(4):327–42.
238. Gehricke J-G, Hong N, Wigal TL, Chan V, Doan A. ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. Pharmacol Biochem Behav. 2011;98(3):485–91.
239. Sacco KA, Creeden C, Reutenauer EL, Vessicchio JC, Weinberger AH, George TP. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res. 2009;107(2):332–3.
240. Silverstone PH, Dadashova R. Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers. Ann Gen Psychiatry. 2012;11(1):1–11.
241. Sofuoglu M, Mouratidis M, Yoo S, Kosten T. Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. Behav Pharmacol. 2006;17(8):731–5.
242. Sofuoglu M, Babb D, Hatsukami DK. Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine Tob Res. 2003;5(6):947–53.
243. Bond RA, Glass M. Use of beta-adrenergic inverse agonists for smoking cessation. Google Patents; 2012.
244. Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT. Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther. 2002;303(2):664–72.
245. Miller DK, Wong EH, Chesnut MD, Dwoskin LP. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther. 2002;302(2):687–95.
246. Wong E. Method of promoting smoking cessation. Google Patents; 2003.
247. Dadashova R, Silverstone PH. Off-label use of atomoxetine in adults: is it safe? Mental Illn. 2012;4(2):319.
248. Keating GM, Jarvis B. Carvedilol. Drugs. 2003;63(16):1697–741.
249. Ollivier J, Durier P, Bussiere J, Gayet J. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension. Eur J Clin Pharmacol. 1990;38(2):S164–6.
250. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol (Oxford, England). 1996;11(4 Suppl):S33–7.
251. Dorset NHS. Shared care guideline for the use of atomoxetine in adults with attention deficit hyperactivity disorder. 2010. cited; Available from: http://www.dorsetccg.nhs.uk/Downloads/aboutus/medicines-management/Shared%20Care%20Guidelines/Shared%20care%20guideline%20for%20Atomoxetine%20use%20in%20adults%202010.pdf.
252. NICE. Cost-effectiveness analysis of interventions to increase uptake and adherence to cardiac rehabilitation programmes. 2013. cited; Available from: https://www.nice.org.uk/guidance/CG172/documents/mi-secondary-prevention-update-appendices-l-n2.
253. Lakshmi SP, Reddy AT, Zhang Y, Sciurba FC, Mallampalli RK, Duncan SR, et al. Down-regulated peroxisome proliferator-activated receptor gamma (PPARgamma) in lung epithelial cells promotes a PPARgamma agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD). J Biol Chem. 2014;289(10):6383–93.
254. Adis Insight. OMS 405. 2012. cited; Available from: http://adisinsight.springer.com/drugs/800035962.
255. Ciccocioppo R. Compositions and methods for prophylaxis and treatment of addictions. Google Patents; 2009.
256. Lakshmi SP, Reddy AT, Zhang Y, Sciurba FC, Mallampalli RK, Duncan SR, et al. Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD). J Biol Chem. 2014;289(10):6383–93.
257. Keith RL. Lung cancer chemoprevention. Proc Am Thorac Soc. 2012;9(2):52–6.
258. Levin D, Bell S, Sund R, Hartikainen S, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58(3):493–504.
259. Home P. Safety of PPAR agonists. Diabetes Care. 2011;34(Suppl 2):S215–S9.
260. Czoski-Murray C, Warren E, Chilcott J, Beverely C, Psyllaki MA, Cowan J. The clinical and cost-effectiveness of pioglita-zone and rosiglitazone in the treatment of type 2 diabetes. Health Technol Assess. 8(13);1–91.
261. 2C receptor agonists. Trends Pharmacol Sci. 2013;34(10):560–70.
262. Bieley HC. Smoking cessation with body weight maintenance and nutritional supplement. Google Patents; 2014.
263. 2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther. 2011;338(3):890–6.
264. 2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology. 2012;37(5):1177–91.
265. Guy EG, Fisher DC, Higgins GA, Fletcher PJ. Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats. Behav Pharmacol. 2014;25(8):775–83.
266. Eisai. News release: lorcaserin meets primary endpoint and confirms proof-of-concept as potential aid for smoking cessation in investigational phase II clinical study. 2014. cited; Available from: http://www.eisai.com/news/news201465.html.
267. Shanahan W, Rose JE, Glicklich A, Stubbe S, Halliday D, Zhang J, et al. Lorcaserin for smoking cessation treatment in cigarette smokers: a randomized phase 2 trial. Denver: American Thoracic Society 2015 International Conference; 2015.
268. Hiatt WR, Thomas A, Goldfine AB. What cost weight loss? Circulation. 2012;125(9):1171–7.
269. Finkelstein EA, Kruger E. Meta- and cost-effectiveness analysis of commercial weight loss strategies. Obesity. 2014;22(9):1942–51.
270. Farid P, Abate MA. Buspirone use for smoking cessation. Ann Pharmacother. 1998;32(12):1362–4.
271. Hilleman DE, Mohiuddin SM, Del Core MG, Sketch MH Sr. Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Intern Med. 1992;152(2):350–2.
272. Cropp CD, Gora-Harper ML. Ondansetron use for smoking cessation. Ann Pharmacother. 1995;29(10):1041–2.
273. Lader M. Assessing the potential for buspirone dependence or abuse and effects of its withdrawal. Am J Med. 1987;82(5):20–6.
274. West R, Hajek P. Randomised controlled trial of ondansetron in smoking cessation. Psychopharmacology. 1996;126(1):95–6.
275. Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Pharmacology, efficacy, and safety of a non-benzodiazepine anxiolytic: review of the side-effect profile of buspirone. Am J Med. 1986;80(3):17–21.
276. Constantino-Casas P, Leon-Gonzalez G, Nevarez-Sida A, Valencia-Huarte E, Garcia-Contreras F. [Cost-effectiveness of anxiolytics in anxiety disorders]. Rev Med Inst Mex Seguro Soc. 2010;48(3):303–8.
277. Awtry TL, Werling LL. Acute and chronic effects of nicotine on serotonin uptake in prefrontal cortex and hippocampus of rats. Synapse. 2003;50(3):206–11.
278. Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, et al. Bupropion and cognitive–behavioral treatment for depression in smoking cessation. Nicotine Tob Res. 2007;9(7):721–30.
279. Spring B, Doran N, Pagoto S, McChargue D, Cook JW, Bailey K, et al. Fluoxetine, smoking, and history of major depression: a randomized controlled trial. J Consult Clin Psychol. 2007;75(1):85–94.
280. Minami H, Kahler CW, Bloom EL, Strong DR, Abrantes AM, Zywiak WH, et al. Effects of depression history and sex on the efficacy of sequential versus standard fluoxetine for smoking cessation in elevated depressive symptom smokers. Addict Disord Treat. 2015;14(1):29–39.
281. Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F, et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation—a randomized trial. Addiction. 1999;94(7):1007–15.
282. Covey LS, Glassman AH, Stetner F, Rivelli S, Stage K. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry. 2002;159(10):1731–7.
283. Niaura R, Spring B, Borrelli B, Hedeker D, Goldstein MG, Keuthen N, et al. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol. 2002;70(4):887.
284. Demyttenaere K, Jaspers L. Review: bupropion and SSRI-induced side effects. J Psychopharmacol. 2008;22(7):792–804.
285. Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005;9(16):1–134, iii.
286. Byford S, Barrett B, Roberts C, Wilkinson P, Dubicka B, Kelvin RG, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive–behavioural therapy in adolescents with major depression. Br J Psychiatry. 2007;191(6):521–7.
287. Kendrick T, Peveler R, Longworth L, Baldwin D, Moore M, Chatwin J, et al. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Randomised controlled trial. 2006;188(4):337–45.
288. Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Libr. 2012;9:CD000191.
289. Jensen EJ, Schmidt E, Pedersen B, Dahl R. Effect on smoking cessation of silver acetate, nicotine and ordinary chewing gum. Psychopharmacology. 1991;104(4):470–4.
290. Stead LF, Lancaster T. Nicobrevin for smoking cessation. Cochrane Libr. 2006;19(2):CD005990.
291. MHRA. MHRA UK public assessment report: Nicobrevin: withdrawn from UK market as risks outweigh benefits. 2011. cited; Available from: http://www.mhra.gov.uk/home/groups/s-par/documents/websiteresources/con114612.pdf.
292. Wanwimolruk S, Wong S, Coville P, Viriyayudhakorn S, Thitiarchakul S. Cigarette smoking enhances the elimination of quinine. Br J Clin Pharmacol. 1993;36(6):610–4.
293. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67(4):554–66.
294. Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr Dis Treat. 2007;3(3):349–64.
295. Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2002;67(2):219–23.
296. Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, et al. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend. 2008;98(1):86–93.
297. Sofuoglu M, Waters AJ, Mooney M. Modafinil and nicotine interactions in abstinent smokers. Hum Psychopharmacol. 2008;23(1):21–30.
298. Martin CA, Lile J, Guenthner G, Anestis JC, Batten SR, Kelly TH. Behavioral effects of modafinil and nicotine, alone and in combination, in tobacco-deprived young adult smokers. J Clin Psychopharmacol. 2014;34(2):278–81.
299. Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, et al. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend. 2008;98(1–2):86–93.
300. Shearer J, Shanahan M, Darke S, Rodgers C, Van Beek I, McKetin R, et al. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Review. 2010;29(3):235–42.
301. Fowler JS, Logan J, Wang GJ, Volkow ND. Monoamine oxidase and cigarette smoking. Neurotoxicology. 2003;24(1):75–82.
302. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Ameli N, et al. Response to transdermal selegiline smoking cessation therapy and markers in the 15q24 chromosomal region. Nicotine Tob Res. 2015;17(9):1126–33.
303. Mospan C. Updates in pharmacotherapy for smoking cessation. J Nurse Pract. 2016;12(6):421–2.
304. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O’Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53(2):136–43.
305. Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, et al. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res. 2012;14(3):377–82.
306. Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther. 1995;58(4):444–52.
307. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010;77(12):859–82.
308. David SP, Lancaster T, Stead LF, Evins AE, Cahill K. Opioid antagonists for smoking cessation. Cochrane Libr. 2006;6(6):CD003086.
309. Berrettini W. Opioid neuroscience for addiction medicine: from animal models to FDA approval for alcohol addiction. Prog Brain Res. 2016;223:253–67.
310. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012;1:CD006219.
311. Mooney ME, Poling J, Gonzalez G, Gonsai K, Kosten T, Sofuoglu M. Preliminary study of buprenorphine and bupropion for opioid-dependent smokers. Am J Addict. 2008;17(4):287–92.
312. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–20.
313. O’Mahony S, Coyle N, Payne R. Current management of opioid-related side effects. Oncology (Williston Park, NY). 2001;15(1):61–73, 7 (discussion 7–8, 80–2).
314. De Lima L, Sweeney C, Palmer JL, Bruera E. Potent analgesics are more expensive for patients in developing countries: a comparative study. J Pain Palliat Care Pharmacother. 2004;18(1):59–70.
315. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, Group R-ES. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389–97.
316. Boekholdt SM, Peters RJ. Rimonabant: obituary for a wonder drug. Lancet. 2010;376(9740):489–90.
317. Cahill K, Ussher Michael H. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd; 2011.
318. Steinberg MB, Foulds J. Rimonabant for treating tobacco dependence. Vasc Health Risk Manag. 2007;3(3):307–11.
319. Cahill K, Ussher M. Can cannabinoid type 1 receptor antagonists help smokers to quit, and could they also reduce the amount of weight gained during the quitting process? 2012;3:CD005353.
320. Neovius M, Narbro K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int J Obesity. 2008;32(12):1752–63.
321. Rosenbaum JF, Fava M, Falk W, Pollack MH, Cohen L, Cohen B, et al. The antidepressant potential of oral S-adenosyl-l-methionine*. Acta Psychiatr Scand. 1990;81(5):432–6.
322. Butterweck V. Mechanism of action of St John’s wort in depression: what is known? CNS Drugs. 2003;17(8):539–62.
323. Rapaport MH, Nierenberg AA, Howland R, Dording C, Schettler PJ, Mischoulon D. The treatment of minor depression with St. John’s wort or citalopram: failure to show benefit over placebo. J Psychiatr Res. 2011;45(7):931–41.
324. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord. 2004;26(5):6.
325. Yang J, He Y, Du YX, Tang LL, Wang GJ, Fawcett JP. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. Clin Ther. 2009;31(2):311–20.
326. Fornal CA, Metzler CW, Mirescu C, Stein SK, Jacobs BL. Effects of standardized extracts of St. John’s wort on the single-unit activity of serotonergic dorsal raphe neurons in awake cats: comparisons with fluoxetine and sertraline. Neuropsychopharmacology. 2001;25(6):858–70.
327. Parsons A, Ingram J, Inglis J, Aveyard P, Johnstone E, Brown K, et al. A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John’s wort for smoking cessation and chromium to prevent weight gain on smoking cessation. Drug Alcohol Depend. 2009;102(1):116–22.
328. Sood A, Ebbert JO, Prasad K, Croghan IT, Bauer B, Schroeder DR. A randomized clinical trial of St. John’s wort for smoking cessation. J Altern Complement Med. 2010;16(7):761–7.
329. Sood A, Prasad K, Croghan IT, Schroeder DR, Ehlers SL, Ebbert JO. S-Adenosyl-l-methionine (SAMe) for smoking abstinence: a randomized clinical trial. J Altern Complement Med. 2012;18(9):854–9.
330. Green T, Steingart L, Frisch A, Zarchi O, Weizman A, Gothelf D. The feasibility and safety of S-adenosyl-l-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. J Neural Transm. 2012;119(11):1417–23.
331. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, et al. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther. 2003;74(6):525–35.
332. Mischoulon D, Fava M. Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76(5):1158S–61S.
333. Gaster B, Holroyd J. St John’s wort for depression: a systematic review. Arch Intern Med. 2000;160(2):152–6.
334. Jacobs MA, Spilken AZ, Norman MM, Wohlberg GW, Knapp PH. Interaction of personality and treatment conditions associated with success in a smoking control program. Psychosom Med. 1971;33(6):545–56.
335. Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psychiatry. 1989;146(3):373–6.
336. Pinder RM, Brogden RN, Speight TM, Avery GS. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs. 1977;13(3):161–218.
337. Mann A, Catterson A, MacPherson A. Toxicity of imipramine: report on serious side effects and massive overdosage. Can Med Assoc J. 1959;81(1):23.
338. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry. 1997;58(2):47–58.
339. Qiumei W, Xiaoxue W. Cost-effectiveness analysis of three therapeutic regimens for depression. China Pharm. 2005;1:027.
340. Pine-Abata H, McNeill A, Murray R, Bitton A, Rigotti N, Raw M. A survey of tobacco dependence treatment services in 121 countries. Addiction. 2013;108(8):1476–84.
341. Perngparn U, Assanangkornchai S, Pilley C, Aramrattana A. Drug and alcohol services in middle-income countries. Curr Opin Psychiatry. 2008;21(3):229–33.
342. Raw M, McNeill A, Murray R. Case studies of tobacco dependence treatment in Brazil, England, India, South Africa and Uruguay. Addiction. 2010;105(10):1721–8.
343. Hao W, Chen H, Su Z. China: alcohol today. Addiction. 2005;100(6):737–41.
344. West R, May S, West M, Croghan E, McEwen A. Performance of English stop smoking services in first 10 years: analysis of service monitoring data. 2013;347:f4921.
345. Public Health England. Alcohol treatment in England 2013–14. 2014. cited; Available from: http://www.nta.nhs.uk/uploads/adult-alcohol-statistics-2013-14-commentary.pdf.
346. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10:Cd008286.
347. Kotz D, Brown J, West R. ‘Real-world’ effectiveness of smoking cessation treatments: a population study. Addiction. 2014;109(3):491–9.
348. Kotz D, Fidler J, West R. Factors associated with the use of aids to cessation in English smokers. Addiction. 2009;104(8):1403–10.
349. West R, Brown J. Theory of addiction. Wiley; 2013.
350. Perkins KA. Improving efficiency of initial tests for efficacy in smoking cessation drug discovery. Expert Opin Drug Discov. 2014;9(11):1259–64.
351. Kaper J, Wagena E, Willemsen M, Van Schayck C. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction. 2005;100(7):1012–20.
352. Bertram MY, Lim SS, Wallace AL, Vos T. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia. Tob Control. 2007;16(4):255–60.
353. Beard E, Vangeli E, Michie S, West R. The use of nicotine replacement therapy for smoking reduction and temporary abstinence: an interview study. Nicotine Tob Res. 2011;14(7):849–56.
354. Foulds J. [Commentary] Improving NRT labeling and correcting public misperceptions. Addiction. 2008;103(8):1379–80.
355. Brose LS, West R, McDermott MS, Fidler JA, Croghan E, McEwen A. What makes for an effective stop-smoking service? Thorax. 2011;66(10):924–6.
356. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44(6):588–97.
357. Hajek P, Smith KM, Dhanji A-R, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med. 2013;11(1):140.
358. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med. 2014;12(1):1.
359. Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA. 2014;311(2):155–63.
360. Benowitz N. Nicotine replacement therapy: what has been accomplished: can we do better? Drugs. 1993;45(2):157–70.
361. Stead Lindsay F, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews: Wiley; 2012.
362. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology. 2000;149(3):198–202.
363. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998;18(4):297–308.
364. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335(24):1792–8.
365. Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol. 2005;95(8):976–8.
366. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis. 2010;8(1):1.
367. ASH. Nicotine replacement therapy, VAT reduction and sales of NRT. 2007. cited; Available from: http://www.ash.org.uk/files/documents/ASH_696.pdf.
368. Jha P, Peto R, Zatonski W, Boreham J, Jarvis MJ, Lopez AD. Social inequalities in male mortality, and in male mortality from smoking: indirect estimation from national death rates in England and Wales, Poland, and North America. Lancet. 2006;368(9533):367–70.
369. Shahab L, McEwen A. Cost-effectiveness of pharmacotherapy for smoking cessation. NCSCT. 2012. cited; Available from: http://www.ncsct.co.uk/usr/pub/B7_Cost-effectiveness_pharmacotherapy.pdf.
370. ASH. Key dates in the history of anti-tobacco campaigning. cited; Available from: http://www.ash.org.uk/files/documents/ASH_741.pdf.
371. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction. 2001;96(11):1547–51.
372. Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy. Tob Control. 2005;14(5):346–55.
373. Silla K, Beard E, Shahab L. Characterization of long-term users of nicotine replacement therapy: evidence from a national survey. Nicotine Tob Res. 2014;16(8):1050–5.
374. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 1999;159(17):2033–8.
375. Gonzales D, Bjornson W, Durcan MJ, White JD, Johnston JA, Buist AS, et al. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prev Med. 2002;22(4):234–9.
376. Brose LS, West R, McDermott MS, Fidler JA, Croghan E, McEwen A. What makes for an effective stop-smoking service? Thorax. 2011;27:2011.
377. Gilpin EA, Messer K, Pierce JP. Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success? Nicotine Tob Res. 2006;8(5):661–9.
378. Perkins KA. Issues in the prevention of weight gain after smoking cessation. Ann Behav Med. 1994;16:46–52.
379. Medicines Control Agency. Zyban (bupropion hydrocholride)—safety update. 2002. cited; Available from: http://www.mca.gov.uk/ourwork/monitorsafequalmed/safetymessages/zyban26702.pdf.
380. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax. 2000;55(12):987–99.
381. Woolacott N, Jones L, Forbes C, Mather L, Sowden A, Song F, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16):245.
382. Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation. Clin Drug Investig. 2009;29(10):655–65.
383. Shearer J, Shanahan M. Cost effectiveness analysis of smoking cessation interventions. Aust N Z J Public Health. 2006;30(5):428–34.
384. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16):1–245.
385. Department of Health. Statistics on NHS stop smoking services in England. 2006. cited; Available from: http://www.ic/nhs/pubs/nhsstopsmokingstats2005to2006q4.
386. Aveyard P, West R. Managing smoking cessation. BMJ. 2007;335(7609):37–41.
387. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17):1195–202.
388. Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94–102.
389. Aubin H-J, Bobak A, Britton JR, Oncken C, Billing CB, Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717–24.
390. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest Journal. 2011;139(3):591–9.
391. Warnier MJ, van Riet EE, Rutten FH, De Bruin ML, Sachs AP. Smoking cessation strategies in patients with chronic obstructive pulmonary disease. Eur Respir J. 2012;4(3);727–34.
392. Kaduri P, Voci S, Zawertailo L, Chaiton M, McKenzie K, Selby P. Real-world effectiveness of varenicline versus nicotine replacement therapy in patients with and without psychiatric disorders. J Addict Med. 2015;9(3):169–76.
393. Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11(3):234–9.
394. Institute for Safe Medication Practices. Strong safety signal seen for new varenicline risks. 2012. cited; Available from: www.ismp.org/docs/vareniclinestudy.asp.
395. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Can Med Assoc J. 2011;183(12):1359–66.
396. Harrison-Woolrych M, Maggo S, Tan M, Savage R, Ashton J. Cardiovascular events in patients taking varenicline. Drug Saf. 2012;35(1):33–43.
397. Svanstrom H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176.
398. Farrell M, Howes S, Bebbington P, Brugha T, Jenkins R, Lewis G, et al. Nicotine, alcohol and drug dependence and psychiatric comorbidity: results of a national household survey. Br J Psychiatry. 2001;179(5):432–7.
399. Gunnell D, Irvine D, Wise L, Davies C, Martin R. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
400. Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ. 2013;347:f5704.
401. Buggy Y, Cornelius V, Fogg C, Kasliwal R, Layton D, Shakir SA. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England. Drug Saf. 2013;36(7):521–31.
402. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline. Drug Saf. 2010;33(4):289–301.
403. Kotz D, Viechtbauer W, Simpson C, van Schayck OCP, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med. 2015;3(10):761–8.
404. Bolin K, Wilson K, Benhaddi H, De Nigris E, Marbaix S, Mork A-C, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries. Eur J Public Health. 2009;19(6):650–4.
405. Zimovetz EA, Wilson K, Samuel M, Beard SM. A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities. J Eval Clin Pract. 2011;17(2):288–97.
406. Mahmoudi M, Coleman CI, Sobieraj DM. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. Int J Clin Pract. 2012;66(2):171–82.
407. Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24(1):51–61.
408. Liberman JN, Lichtenfeld MJ, Galaznik A, Mastey V, Harnett J, Zou KH, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm. 2013;19(2):125–31.
409. Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12(6):574–81.